Senior Product Development Scientist

The petition was approved based on meeting at least three EB-1A criteria: authorship of 13 peer-reviewed journal articles and a conference paper, serving as a reviewer for at least 12 manuscripts, and demonstrating original contributions through 254 citations from 27 countries. Additionally, the petitioner secured significant research funding from the FDA, USP, and NSF, further validating his leading role and expertise.

The petition was approved based on the petitioner's authorship of 27 peer-reviewed articles and 17 abstracts, which garnered 485 citations from researchers in over 40 countries. His work ranked in the top 10% of most-cited publications in pharmacology for several years. Additionally, he completed over 60 peer reviews and received research grants from the NIH and the National Research Foundation of South Korea.

The petition was approved based on the satisfaction of at least three EB-1A criteria: authorship of scholarly articles, participation as a judge of the work of others, and original scientific contributions of major significance. Specific metrics included 8 peer-reviewed publications in elite journals like Nature Microbiology, 260 citations placing him in the top 1% of his field, and the completion of over 20 peer reviews for high-impact journals.

The petition was approved based on 11 peer-reviewed articles and 2 preprints with 236 citations, placing several papers in the top 10% of the field. The petitioner satisfied EB-1A criteria through 11 peer reviews for leading journals, serving as an area chair for an international AI conference, and participating in federal grant reviews. His work on AI transparency and reliability was also recognized for its alignment with U.S. government regulatory initiatives.